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entire microflora of the patients. Besides the improved intrinsic 
activity and broadened spectrum, the extremely high concentrations 
of antibiotics present along the route (i.e. oral) of administration are 
the major reason for the dramatic upheaval of the bacterial ecosystem. 
To cope, Gram-positive bacteria have developed strategies that 
include design as well as combination of various resistance mech- 
anisms, such as: drug efflux or impermeability, alteration of the target, 
inactivation of the antibiotic, and bypass. The majority of the 
antibiotic classes are affected by combinations of resistance mech- 
anisms. For example, tetracyclines can be effluxed outside the cell 
while the ribosomal target is protected; the same bacterium can be 
resistant to quinolones by efflux combined with either target, DNA 
gyrase 1 or topoisomerase IV, modification or sequential mutations 
in the two targets. High-level resistance to glycopeptides is due to 
synthesis of new peptidoglycan late precursors with low afinity for 
the drugs and to removal of the previous susceptible target. When 
present in the same host, the two different mechanisms usually 
contribute in more than an additive fashion to the high level of 
resistance. Various examples of this combinatorial approach to 
resistance which allows bacteria to survive very high local concen- 
trations of antibiotics at the infected site will be discussed. 
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In the past few decades, molecular technology has definitely found 
its way into the clinical microbiology laboratory DNA probing and 
amplification belong to the standard repertoire for diagnostic pur- 
poses, whereas also for molecular typing of pathogenic micro- 
organisms various procedures have been developed and implemented 
in the day-to-day routine of many medical microbiology centers. A 
current disadvantage of many of these molecular identification 
schemes is that relatively little information on typing system charac- 
teristics such as discriminatory index, reliability and reproducibility 
is available. For this reason, comparative analyses of different typing 
techniques are of pivotal importance. Aso, multicentered comparison 
of the efficacy of a single technique is as important: this will provide 
insights into assay reproducibility and the possibility for establishing 
large typing-database networks. An increasing number of studies 
describing internauonal collaborative efforts for standardization of 
typing technology are entering the public domain and many of them 
focus on Gram-positive microorganisms that have acquired multiple 
resistance against antimicrobial agents. Examples described for agents 
such as methicillin-resistant Staphylococcus atrreus, penicillin-resistant 
pneumococci and vancomycin-resistant enterococci will be discussed 
and the current gold standards will be defined. 
I F )  Resistance to streptogramins and related 
antibiotics in Gram-positive bacteria 
be an increase of the efflux of the antibiotics or a decrease in the 
binding affinities to their distinct 50s ribosome targets. A number of 
different genes encoding proteins involved in each ofthe mechanisms 
have been found in Gram-positive bacteria. The conserved regions 
of these genes have been used to design degenerate primers useful for 
their screening. The reason why some staphylococcal plasmids co- 
carry two genes encoding resistance to streptogramin A by two 
distinct mechanisms is not yet known. 
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A variety of pathogens are implicated in LRTIs, with the most 
important being Streptococcus pneumoniae, Haemophilux inzuenzae and 
Moraxella catarrhalis. However, while the most commonly identified 
pathogen in community-acquired pneumonia (CAP) is Streptococcus 
pneumoniae, the atypical pathogens such as Mycoplasma pneumoniae, 
Chlamydia pneumoniae and Legionella pneumoniae also play an 
important role. In acute bacterial exacerbations of chronic bronchitis, 
H .  influenzae or Streptococcus pneumoniae are identified as the causative 
pathogen more often than M .  catarrhalis or Staphylococcus aureus, while 
C. pneumoniae and M .  pneumoniae are less fkequently isolated, being 
implicated in up to 5% of cases. Ideally, therefore, empirical antibiotic 
therapy for LRTIs must provide cover for all the pathogens listed 
above, including atypical organisms. The increasing incidence of 
penicillin-resistant Strqptococcus pneumoniae in many countries may 
reduce the effectiveness of beta-lactam antibiotics, which are also not 
active against the atypical pathogens. Many strains of penicillin- 
resistant pneumococci have reduced susceptibility to other classes of 
antibiotics, particularly the macrolides, which also have weak activity 
against H. inzuenzae. In contrast, the fluoroquinolones are bacteri- 
cidal, a feature which may be important for eliminating bacteria from 
the site of infection. Grepafloxacin is one of a group of newly 
introduced fluoroquinolones with potent activity against respiratory 
pathogens, including penicillin- and macrolide-resistant pneumo- 
cocci, beta-Iactamase-producing H. infuenzae and atypical organ- 
isms. A multicenter microbiological surveillance study conducted in 
1998 in European Union countries demonstrated that resistance to 
grepafloxacin in respiratory pathogens is very low: 100% of H. 
infuenrae (n=586) and M .  catarrhalis (n=510) strains, 99.5% of 
Streptococcus pneumoniae (n= 1252) and 98.2% of methicillin- 
susceptible Staphylococcus aureus strains. 
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Well-characterized mechanisms of resistance to streptogramins 
involve either streptogramin inactivation by streptogramin A acetyl- 
transferases and streptograminj3 lactonases or the alteration of the 23s 
rRNA by adenine methylases, which inhibits binding of strepto- 
gramin B, macrolides and lincosamides to their targets. The 
mechanism of resistance to streptogramin A or to streptogramin B 
conferred by related ATP-binding proteins remains unclear. It could 
L s9 I Pharmacokinetics and pharmacodynamics of 
the fluroquinolones: how important is tissue 
penetration? 
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The efficacy of an antibiotic is closely related to its pharmacokinetic 
and pharmacodynamic features. In respiratory tract infections, 
pharmacokinetics and pharmacodynamics are relevant at a number of 
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sites, including the lumen ofthe airways, the mucosal cell surface, the 
bronchial tnucosal tissue, epithelial lining fluid and within the 
alveolar macrophages. Antibiotic therapy should be directed to cover 
the key pathogens, but data on antibiotic penetration to these 
infection sites are relevant. Thus an antibiotic used in respiratory tract 
infections should demonstrate good penetration into respiratory 
tissues, as well as potent activity against respiratory pathogens. A long 
terminal half-life allowing once-daily dosing is advantageous because 
New advances in the diagnosis and 
treatment Of fungal infections 
Overview of the diagnosis of systemic fungal 
infections 
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it is convenient for the patient and may therefore aid compliance. 
However, tissue penetration should not be achieved at the expense 
of therapeutic serum concentrations, especially in pneumonia, where 
pneuniococcal infections in particular may be associated with 
bactereiiiia. Treatment of lower respiratory tract infection in the 
community is largely empirical, and the broad-spectrum anti- 
microbial activity, tissue distribution and efticacy and safety profiles 
of fluoroquinolones indicate that they have a place in such infections. 
Aiiiong the new quinolones, grepafloxacin demonstrates excellent 
activity against the important community-acquired respiratory 
pathogens and is highly concentrated in lung tissues, attaining levels 
many times higher than the corresponding serum level and con- 
siderably above the MICW for relevant bacterial pathogens. At the 
same time, daily doses of 400 mg and 600 mg result in serum levels 
above the MICW for key pathogens, including Streptococcirs 
prierrmoniae, and the extended half-life of 12 h allows once-daily 
dosing . 
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community-acquired pneumonia and acute 
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Newer fluoroquinolones such as grepafloxacin have denionstrated 
efficacy in the treatment of community-acquired pneumonia and 
acute bacterial exacerbations of chronic bronchitis (ABECB). In a 
recent large community-acquired pneumonia study, 10 days treat- 
ment with grepafloxacin 600 nig once daily was found to be clinically 
and microbiologically equivalent to 10 days of clarithromycin 500 mg 
twice-daily Clinical success rates in patients infected with Streptococcus 
pneurnoniac, Haemoplrilus ir!puenzae or Moraxella cararrkalis were 80% 
in the grepafloxacin group and 73% in the clarithroniycin group (not 
significant). I n  patients infected with atypical pathogens (n=57), 
response rates were 91% in the grepafloxacin-treated group and 82% 
of thow receiving clarithromycin (not significant). 
I n  the prevailing cliinate of limited healthcare resources, the costs 
associated with treatment have become increasingly important. Thus 
shortening or modifying treatnient regimens without loss of efficacy 
could have benefits. In the treatment of ABECB, a 5-day course of 
grepafloxacin 400 mg once-daily has been shown to be clinically as 
effective as 10  days of clarithromycin 500 nig twice-daily At the post- 
treatment assessment, bacteriologic success was higher in patients 
receiving 5 days grepafloxacin than in those receiving 10 days 
clarithromycin, particularly with H .  irq'luenzae (88% versus 56%, 
P<O.OOl) or H .  parair!fluenzae (94% versus 51%, P<0.001). In 
addition, eradication of pathogens from sputum occurred signi- 
ficantly more rapidly in grepafloxacin-treated patients (2 days) than 
in those receiving clarithromycin (6 days) (P<0.001). All treatments 
were well tolerated, with the most conimon adverse events being 
nausea, vomiting and abnormal taste. These data indicate that 
grepafloxacin is a potent antibiotic for the treatment of coniniunity- 
acquired LRTIs, with advantages in pathogen eradication compared 
to clarithrornycin in patients with chronic bronchitis. 
Over the last two decades we have seen an increase in the nunibcr of 
systemic fungal infections, in particular, those due to opportunistic 
systemic pathogens. This is due to an increase in the population of 
imiiiunoconipromised hosts, including those with AIlX. Candida is 
the most conimon systemic fungal pathogen worldwide. Crypto- 
coccosis is now seen rnuch more often because of its high prevalence 
in AIDS patients, and up to 20%) of these patients inay develop it, 
depending on what part of the world they live in. Aspeyilliis is a innjor 
cause of mortality i n  leukemics and in hone iiiarrow and solid organ 
transplantation, and the number of these infections is increasing a$ 
the use of these therapeutic techniques increases. Early diagnosis arid 
treatment of these infectious is essential for an optimal prognoris. 
Diagnosis of opportunist systemic fungal infections is difficult. 
Cryptococcosis and infections caused by diinorphic fungi are 
relatively easy to diagnose, providing the correct tests are done. 
However, difficulty is encountered with the diagnosis of invaqive 
aspergillosis and candidosis. With Candida the occurrence of com- 
mensal yeasts can be confusing, so that the niere isolation of yeasts, 
unless it is froin ,I normally sterile site, means little. C a d i d a  
septicemia is helpful in diagnosing deep seated infection but transient 
candideniia which is of no clinical relevance also occurs. With 
Aspcgillnr there is difficulty in isolating the organism and only less 
than 30% of patients with invasive aspergillosis are positive by culture. 
Serology can play a useful role for some disease but for aspergillosis 
and candidosis the tests lack sensitivity and specificity. Antibody 
testing is giving way to tests for antigens, usually polysacchdride 
antigen, and now commercial kits are available for these tests. 
However, antigen tests lack sensitivity. Testing for fungal metabolites 
has been attempted, particularly for Caridida, but so far this has met 
with only limited s~iccess. The iiiost promising way forward would 
seem to be molecular diagnosis based on PCR testing for fungal 
DNA. There is much current work in this area but the tests 
developed so far are still to be fully evaluated. 
I s12 I New developments in the molecular diagnosis 
of fungal infections 
J. Uille. Inst. of Mirwhiolofiy, Clinical Bactcriolosqy Lab, Lousawnc, 
Swirzerland 
Molecular diagnosis of fungal infections is needed for several reawn\:  
an increase in the nuniber of patients at risk, of cases, of species of 
yeasts and ftingi involved, of resistant fungi, and ~ l s o  thc limits of 
conventional diagnostic approaches. Broad spectrum or restricted to 
a single species, genoinic amplification methods such as PCR con-  
prise the following steps: DNA extraction, selection of primers, 
amplification protocols, detection of amplification products, vnlida- 
tion, and clinical studies. Extraction offungal DNA IS generally iiiore 
difficult than bacterial DNA. Target for priiners ideally should be 
present in multiple copies (such as ribosomal or mitochondria1 
targets). They can be either genus (Cawdido, Aspetgillus), or species 
(C. albicans, C. krnsri), specific or broad raiige (pan fungal), followed 
by REA or probing of the amplification product. Careful validation 
ofthe molecular test in a clinical setting is important. These last yem, 
two main problems have been addressed: the molecular diagnosis of 
invasive candidiasis in blood or normally sterile fluids, and of invasive 
